Skip to content
QuantMundi
AustraliaAustralia·Stock·ASX (Australia)

CSL Limited (CSL.AX)

Health Care · Biotechnology · Asia-Pacific

Optimize with this asset

Price in AUD, last 5 years

Last price
A$196.14 (Oct 22, 2026)
1-year return
-8.8%
3-year annual return
-3.7%
5-year annual return
-6.4%
1-year volatility
40.9%
Max drawdown (5Y)
-69.3%
Market cap (approx.)
US$66.0B
History available
since Jan 2, 2014

About CSL Limited

CSL Limited (CSL.AX) is a stock from Australia that trades on ASX (Australia) in AUD. It operates in the health care sector, Biotechnology industry. It's part of the S&P/ASX 50.

Over the last year its price fell 8.8% in AUD, with annual volatility of 41%: a quite volatile asset. Its worst drop over the last five years was 69.3% from a peak.

If your currency isn't the AUD, your real return will also depend on the exchange rate. In the optimizer you can choose your currency (USD, EUR, MXN, BRL, CLP, COP, PEN or ARS) and the calculation includes that currency risk.

How does it fit into a portfolio? What matters is not just its risk on its own, but how much it moves together with your other assets. Add it to your list and the optimizer will show you what weight the model would give it and why.

Other health care assets in Asia-Pacific

Assets similar to CSL Limited
Asset1 year1Y returnVolatilityMarket cap
China
WuXi AppTec Co., Ltd.2359.HK · Stock · Health Care
+76.6%44%US$71.3B
Japan
Chugai Pharmaceutical Co., Ltd.4519.T · Stock · Health Care
-6.0%40%US$69.2B
Japan
Takeda Pharmaceutical Company Limited4502.T · Stock · Health Care
+53.0%23%US$64.5B
Japan
HOYA Corporation7741.T · Stock · Health Care
+15.3%30%US$56.0B
South Korea
Samsung Biologics Co.,Ltd.207940.KS · Stock · Health Care
-24.5%43%US$47.8B
India
Sun Pharmaceutical Industries LimitedSUNPHARMA.NS · Stock · Health Care
+4.9%19%US$44.5B
Australia
ResMed Inc.RMD.AX · Stock · Health Care
-14.8%30%US$34.3B
South Korea
Celltrion, Inc.068270.KS · Stock · Health Care
+14.9%42%US$33.4B

Disclaimer: Educational and simulation tool. It is not investment advice or a personalized recommendation. Past performance does not guarantee future results. Data for educational purposes; it may be delayed or contain errors.